Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy

Overview of attention for article published in Frontiers in oncology, December 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (71st percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

So far, Altmetric has seen 10 X posts from 9 X users, with an upper bound of 33,504 followers.

RT @JAX_CKB: Phase I #clinicaltrial of a dendritic cell vaccine targeting #HER2 in solid #tumors shows preliminary clinical benefit and gr…

RT @NCIResearchCtr: #CCRAdvance Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Cl…

RT @NCIResearchCtr: #CCRAdvance Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Cl…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 6 additional X posts.